Tenax Therapeutics Welcomes Renowned Expert to Its Scientific Advisory Board
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing treatments for cardiovascular and pulmonary diseases. This has recently expanded its Scientific Advisory Board (SAB) with the addition of a distinguished expert in cardiovascular medicine, Dr. Javed Butler. This strategic move comes as the company advances its Phase 3 investigation of oral levosimendan, aimed at addressing the needs of patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF), a condition currently with limited therapeutic options.
Tenax Therapeutics’ Chief Medical Officer, Stuart Rich, M.D., expressed his enthusiasm for Dr. Butler’s appointment. Dr. Rich highlighted Dr. Butler’s extensive experience and reputation as a leading clinical trialist in the field, which is expected to provide invaluable insight into the efficacy evaluation of TNX-103 (oral levosimendan) in PH-HFpEF.
Dr. Butler’s career has been distinguished by his leadership roles at Baylor Scott and White Research Institute and Baylor Scott and White Health, where he serves as President and Senior Vice President, respectively. His academic tenure as Distinguished Professor of Medicine at the University of Mississippi and his prolific research record, which includes more than 1,100 peer-reviewed publications, further establish his authority in cardiovascular medicine.
The SAB, chaired by Sanjiv Shah, MD, a pioneer in the field of HFpEF, has been a cornerstone in guiding the design and execution of Tenax Therapeutics’ clinical trials since its formation in 2018, prior to the HELP study. The Board’s collective expertise is expected to be instrumental in the development of levosimendan, a novel class of drugs that may offer significant benefits to patients with PH-HFpEF. The addition of Dr. Butler to the SAB is seen as a reflection of the potential impact of the company’s research on a disease that currently lacks effective treatments.
The recent approval by the U.S. Food and Drug Administration for the planned Phase 3 trial of oral levosimendan further demonstrates the Company’s commitment to advancing the understanding and treatment of PH-HFpEF. The role of the SAB is expected to be critical in this effort, leveraging their collective knowledge and experience to guide the development process.
The appointment of Dr. Javed Butler to the Scientific Advisory Board of Tenax Therapeutics is a significant step forward in the company’s efforts to address cardiovascular and pulmonary diseases. His extensive background and accomplishments in cardiovascular medicine are expected to contribute significantly to the development of oral levosimendan. As Tenax Therapeutics continues to advance its clinical trials, the expertise of its SAB members will be critical to addressing the high unmet medical need of patients with PH-HFpEF. The company’s ongoing efforts in this area underscore its commitment to improving patient outcomes and quality of life for those affected by these challenging diseases.
Source link
